Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Einstein Technologies (Cancer) Einstein Reference Number Title of Patent Application Abstract Senior Einstein Investigator Link to NonProvisional Patent Application C-744 Inhibitors of saporin-L1 are disclosed, as are related compositions and Saporin-L1 inhibitors and uses thereof, in particular in cancer therapy that employs saporin-L1uses thereof linked immunotoxins. Vern Schramm US 12/932,051 C-753 The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumorhoming nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonuceotide, (ii) replacing one or more nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing the it with one or more nucleoside or nucleoside analogs; or (2) preparing a naive combinatorial aptamer, internalizing nucleic acid or tumor-homing nucleic acid prodrug library, and running iterative rounds of selection for the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of treating or preventing cancer and/or viral infection, the method comprising administration of the oligonuleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells. Matthew Levy PCT/US11/00754 C-783 Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the Selective betagastrointestinal tract. The compounds, compositions and methods glucuronidase inhibitors can be for inhibiting bacterial β-glucuronidases and for improving as a treatment for side efficacy of camptothecin-derived antineoplastic agents or effects of camptothecin glucuronidase-substrate agents or compounds by attenuating the side antineoplastic agents effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds. Sridhar Mani PCT/US2010/059690 C-797 Stat3 activation as a Methods are disclosed for determining classification and prognosis of marker for classification patients with diffuse large B-cell lymphoma (DLBCL) using activation and prognosis of dlbcl of signal transducer and activator of transcription 3 (STAT3). patients B Hilda Ye PCT/US2012/066782 C-800 Targets for diagnosis, prognosis and therapy of Methods are disclosed for diagnosis, prognosis and therapy of acute acute myeloid leukemia myeloid leukemia and myelodysplastic syndromes using interleukin 1 and myelodysplastic receptor accessory protein and other targets. syndromes Ulrich Steidl PCT/US2012/050062 C-801 A method of treating a tumor in a subject, or reducing or preventing metastasis of a tumor in a subject, is provided comprising administering to the subject an amount of a bacteria labelled with, or comprising, one or more radionuclides so as to treat the tumor in the subject, or so as to reduce or prevent metastasis of the tumor in the subject. Radiobacteria-containing compositions and pharmaceutical compositions are also provided. Ekaterina Dadachova PCT/US2012/023785 C-812 Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an Therapeutic and HLX gene in the subject, or an agent which inhibits activity of an diagnostic target gene in expression product of the HLX gene, and also for diagnosing a subject acute myeloid leukemia as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided. Ulrich Steidl PCT/US2012/036303 C-818 Myosin-iia s1943 phosphorylation as a marker of tumor invasion Anne Bresnick 13/419,805 Methods of preparing targeted aptamer prodrugs Radiobacteria for therapy of cancer Methods and kits are provided for determining if cells of a tumor in an organ or a tissue in a subject are likely to invade another organ or tissue in the subject and for determining if a cancer in a subject is likely to metastasize. ***Please note these technologies are representative of the Einstein Intellectual Property Portfolio that are currently published patents/patent applications and available for licensing. For non-published technologies please contact [email protected]. Version March 2016 Einstein Technologies (Cancer) Abstract Senior Einstein Investigator Link to NonProvisional Patent Application Methods are disclosed for identifying activators and inhibitors of actions of interleukin-34 (IL-34) that are independent of the colony stimulating factor- 1 (CSF-1) receptor (CSF-1R) and play a role in development, homeostasis and disease. Evan R Stanley PCT/US2014/38590 C-920 Macrophage-synthesized Methods and compositions are provided for inhibiting metastasis of a ccl3 promotes breast tumor in a subject, or of inhibiting progression of a primary tumor in a cancer metastasis subject which requires macrophages for progression. Jeffrey Pollard 13/860,109 C-963 Identification and use of Methods are provided for diagnosing and treating a blood cancer or a new tumor-promoting myelodysplastic syndrome in a subject. Associated compositions and gene in hematological kits therefor are also provided. malignancies Ulrich Steidl PCT/US2013/70227 C-976 Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated A selective high-affinity mutant PD-1 polypeptide fused to an immunoglobulin domain immune stimulatory polypeptide are provided. Further provided are methods of using a reagent and uses thereof composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection. Steve Almo PCT/US2014/15235 C-978 Small- molecule binding site on pro-apoptotic bax Methods are provided for identifying an agent as a selective inhibitor regulates inhibition of of a Bcl-2-associated x-protein (BAX). bax activity Evripidis Gavathoiotis PCT/US2014/11213 Ulrich Steidl PCT/US2014/24239 Einstein Reference Number C-891 C-988 Title of Patent Application Il-34 receptor assays and uses thereof Pak1 inhibition for treatment of acute myeloid leukemia and myelodysplastic syndromes Methods are disclosed for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) using inhibition of p21 protein (Cdc42/Rac)-activated kinase (PAK1). ***Please note these technologies are representative of the Einstein Intellectual Property Portfolio that are currently published patents/patent applications and available for licensing. For non-published technologies please contact [email protected]. Version March 2016